Ryan McDonald, Associate Editorial Director for CancerNetwork® and the journal ONCOLOGY, has been with the team since November 2022 and has been with MJH Life Sciences since February 2020.
He is a graduate of Temple University, where he studied journalism and minored in political science and history. He considers himself a craft beer snob and would like to open a brewery in the future. He always says he'll try any brewery or restaurant twice.
During his spare time, he can be found rooting for all major Philadelphia sports teams (he was heartbroken to see the Union lose the 2022 MLS Cup and the Phillies lose the 2022 World Series). Follow Ryan on Twitter @RMcDonald11 or email him at firstname.lastname@example.org.
FDA Approves New Dosing Regimens, Indications for Capecitabine Across Multiple Cancer TypesDecember 15th 2022
The FDA’s approval of new indications and dosing regimens of capecitabine across several cancer types, including breast cancer and colon cancer, marks the first drug to receive an update under the agency’s Project Renewal program.
Ibrutinib-Venetoclax Combo Appears Effective in Previously Untreated Waldenström MacroglobulinemiaDecember 11th 2022
Patients with previously untreated Waldenström Macroglobulinemia—a rare form of blood cancer—derived fast and durable responses after receiving treatment with ibrutinib plus venetoclax, according to findings from a prospective phase 2 trial presented at 2022 ASH Annual Meeting.
IV, Subcutaneous Forimtamig Induces Effective, High Response Rates in Relapsed/Refractory Multiple MyelomaDecember 10th 2022
The findings, according to the lead study author, demonstrate that treatment with forimtamig delivered intravenously or subcutaneously may elicit long-term responses in patients with relapsed or refractory multiple myeloma.
Fixed-Duration Glofitamab Regimen Elicits Early, Durable Responses in Heavily Pretreated Patients with Relapsed/Refractory Mantle Cell LymphomaDecember 10th 2022
The use of a fixed-duration regimen of glofitamab several days after pretreatment with obinutuzumab was associated with high complete responses among a group of heavily pretreated patients with relapsed or refractory mantle cell lymphoma.
FDA Grants Accelerated Approval to Mirvetuximab Soravtansine for Subset of Platinum-Resistant Ovarian CancerNovember 14th 2022
The FDA has granted mirvetuximab soravtansine-gynx an accelerated approval for the treatment of patients with folate receptor-α-positive platinum-resistant ovarian cancer based on results from the phase 3 SORAYA study.
Blood-Based Biomarkers May Predict Disease Response in Advanced Urothelial CarcinomaSeptember 11th 2022
At ESMO 2022, peripheral blood samples taken from patients with advanced or metastatic urothelial carcinoma treated on the phase 3 JAVELIN Bladder 100 trial showed there may be a potential to predict disease response to avelumab.
Pembrolizumab Plus Concurrent Chemoradiation Continues to Induce Durable Responses in Previously Untreated Stage III NSCLCJune 7th 2022
Patients with previously untreated, locally advanced stage 3 non–small cell lung cancer continue to derive a benefit from pembrolizumab with concurrent chemoradiation followed by additional pembrolizumab after more than 2 years of follow-up.
First-line Ribociclib-AI Combo Associated with Better Symptom-Related QOL Vs Abemaciclib-AI in HR+/HER2− Advanced Breast CancerJune 6th 2022
Results of a matching-adjusted indirect comparison study showed that patients with HR-positive/HER2–negative advanced breast cancer treated with ribociclib and an aromatase inhibitor were more likely to have better symptom-related quality of life than patients who received abemaciclib and an aromatase inhibitor.
Preliminary Results Show Second-line Lurbinectedin Plus Pembrolizumab Safe, Effective in Relapsed SCLCJune 6th 2022
Preliminary findings of data from the phase 1/2 LUPER study demonstrate that treatment with lurbinectedin combined with pembrolizumab elicits promising efficacy in patients with metastatic small-cell lung cancer that has failed to respond to chemotherapy.
Long-Term Follow-Up Continues to Show Acalabrutinib-Based Regimens Superior to Obinutuzumab Plus Chemo in Treatment-Naïve CLLJune 4th 2022
At approximately 5 years of follow-up, findings from the phase 3 ELEVATE-TN study show that treatment outcomes are more favorable with acalabrutinib with or without obinutuzumab compared with obinutuzumab and chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Despite Increased Use of Telemedicine for Cancer Care During COVID-19, Disparities PersistMay 26th 2022
The findings of this retrospective study of more than 25,000 patients with cancer newly diagnosed during the COVID-19 pandemic highlight a need to reduce the inequities in telemedicine use for cancer care, according to the study’s lead author.
ALPINE Trial Points to Favorability of Zanubrutinib in Relapsed/Refractory CLL/SLL Versus IbrutinibJune 11th 2021
Data from EHA 2021 showed that zanubrutinib was associated with better outcomes over ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Compared With ASCT, KCd Shows Potential Utility for Newly Diagnosed, Transplant-Eligible MMJune 8th 2021
Compared to upfront autologous stem cell transplantation for newly diagnosed, transplant-eligible patients with multiple myeloma, carfilzomib consolidation with cyclophosphamide and dexamethasone produced noninferior results.
CLEAR Study Readout Shows Survival Enhancement With Lenvatinib Plus Pembrolizumab Versus Sunitinib in Frontline RCCFebruary 14th 2021
Better progression-free survival, as well as improved responses, were seen when lenvatinib was combined with either pembrolizumab or everolimus versus standard-of-care sunitinib in the treatment of patients with advanced renal cell carcinoma receiving therapy in the frontline setting.
Dual PD-1 and HER2 Blockade Plus Chemotherapy Proves Effective for Treatment of HER2+ Gastric, GEJ CancerJanuary 15th 2021
Statistically significant improvements in median progression-free survival were observed in patients with HER2- amplified disease who were treated with pembrolizumab in combination with trastuzumab and cisplatin plus capecitabine compared with those without HER2-amplified disease.
KTE-X19 Proves Comparable to Current Therapies in Treating High-Risk MCLMay 31st 2020
When compared to currently approved therapies, KTE-X19 demonstrated comparable pharmacologic and clinical outcomes in patients with high-risk MCL characteristics versus lower-risk characteristics defined by tumor protein TP53 mutation or high Ki-67 proliferation index.
Cancer Progression Linked to Increased Risk of Death Within 30 Days of COVID-19 DiagnosisMay 28th 2020
Disease progression and treatment with hydroxychloroquine and azithromycin were associated with increased all-cause 30-day mortality in patients with cancer compared to patients either in remission or with no evidence of disease, according to data presented during a 2020 ASCO Virtual Scientific Program press briefing.